Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 15th 2022

Addressing Cancer Health Disparities in a Multilateral Collaboration in an Independent Community Cancer Clinic: Translating Words Into Action

Kashyap Patel, MD Hirangi Mukhi, BS Anjana Patel, BSc Niyati Nathwani, MD Dhwani Mehta, MS Jennifer Sherak, MBA Natasha Clinton, MSN, APRN, AOCNP Holly Pisarik, JD Benjamin Brown, BS Sara Rogers, PharmD Mary Kruczynski Nicolas Ferreyros, BA Ted Okon, MBA

No One Left Behind, a program to provide financial assistance and access to cancer care at Carolina Blood and Cancer Care Associates in South Carolina, will be discussed during a session of the Community Oncology Alliance 2022 Community Oncology Conference.

March 15th 2022

Patel et al, Appendix B

March 14th 2022

COA 2022 Preview: Leaders Excited About Seeing Colleagues in Person

Mary Caffrey

The first in-person Community Oncology Alliance (COA) meeting in 2 years will feature sessions on practice management, health disparities, and more. A virtual option is available.

March 9th 2022

Oncology Alternative Payment Models: Lessons From Commercial Insurance

Elizabeth Shaughnessy, MA David C. Johnson, MD, MPH Aaron J. Lyss, MBA Ravi B. Parikh, MD, MPP Steven R. Peskin, MD, MBA, MACP Blase N. Polite, MD, MPP Julie A. Royalty Bhuvana Sagar, MD, MBA Erin Smith, JD Lindee Goh, PhD

Developing alternative payment models for commercial populations in specialties such as oncology is rife with practical challenges. Leading payers and practices share lessons to date.

February 21st 2022

CMS Official Cites OCM as Example of Biosimilar Success

Mary Caffrey

Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.

February 16th 2022

From the Editor-in-Chief: From the Earth to the Moon (and Back)

Joseph Alvarnas, MD

The president’s aim is a 50% reduction in age-adjusted cancer deaths by 2047. This goal seems audacious, but it is likely achievable.

February 15th 2022

Tumor Mutational Burden May Help Predict Immunotherapy Response in Metastatic NSCLC

Matthew Gavidia

Response to immunotherapy and survival outcomes were found to be significantly associated with tumor mutational burden in patients with stage IV non-small cell lung cancer.

February 14th 2022

Emory’s Winship Joins AccessHope as Collaboration Partner

Mary Caffrey

AccessHope is a program that allows patients and community oncologists to tap into the expertise of City of Hope, often through electronic sharing of records so the patient does not have to travel.

February 14th 2022

From Our Partners: Schleicher, Dickson Take New Roles at Tennessee Oncology

Hayden E. Klein Mary Caffrey

The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.

February 2nd 2022

What We’re Reading: Cancer Moonshot Returns; New Omicron Subvariant; Drug Overdose Suicide Rates

AJMC Staff

President Biden announced he would bring back the Cancer Moonshot initiative that launched in the Obama administration; the World Health Organization said the Omicron subvariant, BA.2, appears to have the same severity as the original Omicron variant; cases of suicide by drug overdose increased in young people, older adults, and non-Hispanic Black women.

January 31st 2022

COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk

Mary Caffrey

The Oncology Care Model (OCM) is set to expire June 30, 2022. With no successor on the horizon, respondents to a recent survey by the Community Oncology Alliance (COA) say features such as dedicated navigators and weekend appointments could be reduced or lost if revenues that supported them are eliminated.

January 11th 2022

Management of TRK Fusion Cancer: Evaluating Targeted Therapies - Participating Faculty

January 11th 2022

Diagnosis and Management of TRK Fusion Cancer

Shivaani Kummar, MD, FACP Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Josh J. Carlson, PhD, MPH Sean D. Sullivan, PhD, MSc, RPh Ulrik Lassen, MD, PhD Noah Federman, MD

January 11th 2022

Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

Josh J. Carlson, PhD, MPH Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Noah Federman, MD Ulrik Lassen, MD, PhD Shivaani Kummar, MD, FACP Sean D. Sullivan, PhD, MSc, RPh

January 3rd 2022

Tennessee Oncology Names Dr Stephen Schleicher CMO, Dr Natalie Dickson CSO

Hayden E. Klein

Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).

Burt Zweigenhaft, PhD, DLitt, Upstream Partners

December 20th 2021

CONFERENCE COVERAGE: Asembia 2021

Matthew Gavidia

Coverage from the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.

December 20th 2021

PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer

Laura Joszt, MA

Marcus Neubauer, MD, chief medical officer, The US Oncology Network. He is an expert in precision medicine, value-based care, and clinical pathways.

December 20th 2021

PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider

Laura Joszt, MA

Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.

December 20th 2021

In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract

Mary Caffrey

Vertical integration of payers and pharmacy benefit managers (PBMs) took flight with the mergers of Aetna and CVS Health and of Cigna and ExpressScripts. Panelists at Patient-Centered Oncology Care® said the shift has filtered down to affect access at the practice level.

December 19th 2021

Panel Discusses the Ongoing Evolution of Remote Patient Care

Maggie L. Shaw

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

December 19th 2021

PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?

Laura Joszt, MA

Karen Winkfield, MD, PhD, is the executive director of the Meharry-Vanderbilt Alliance, a strategic partnership between Meharry Medical College and Vanderbilt College of Medicine, Nashville, Tennessee. She is also Ingram Professor of Cancer Research and professor of radiation oncology, Vanderbilt-Ingram Cancer Center.

December 19th 2021

PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now

Laura Joszt, MA

The Oncology Care Model (OCM) is scheduled to end in just a few months, but with no new model in place to succeed it and practices still struggling during the pandemic, CMS should allow OCM to continue, said Kashyap Patel, MD, a co-chair of Patient-Centered Oncology Care® and the current president of the Community Oncology Alliance. He is CEO of Carolina Blood and Cancer Care Associates.

December 19th 2021

PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology

Allison Inserro

Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.

December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen

Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.

December 9th 2021

Mental Health Distress Impacting Cancer Patients, Says New Cardinal Health Survey of Oncologists

More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.

December 8th 2021

Flatiron Health Leverages Expertise With Real-World Data to Examine Cancer Care Disparities

Mary Caffrey

November 23rd 2021

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

Matthew Gavidia

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

November 22nd 2021

Dr Karen van Caulil: End of Oncology Care Model Could Leave Gap in Comprehensive Care

Hayden E. Klein

Karen L. van Caulil, PhD, president and CEO of Florida Alliance for Healthcare Value, discusses the potential gap in care that may occur with the end of the Oncology Care Model.

November 22nd 2021

With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?

Gianna Melillo

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

clipart images of an apple, pill bottle, healthcare forms, doctors, hand holding a heart, piggy bank with a calculator, and a stack of money

November 20th 2021

US Oncology Network, Tennessee Oncology Tout Medicare OCM Savings

Skylar Jeremias

A report from the Centers for Medicare and Medicaid Innovation confirmed that practices within the US Oncology Network and Tennessee Oncology participating in the Oncology Care Model (OCM) program have contributed significant savings to the agency.

...

11 12 13 14 15 16 17 18 19

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions